Radiofrequency treatment with Lonsurf and Avastin for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests if adding a special radiofrequency treatment to the drugs Lonsurf (TAS-102) and Avastin (bevacizumab) can help people whose colorectal cancer has spread to the liver and has not responded to previous treatments. It is for patients with limited options who have already tried at least two standard chemotherapy regimens.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to your liver.
- You have already tried at least two standard chemotherapy treatments and they no longer work or you cannot take them.
- You are 18 years or older and able to take pills by mouth.
- You are in reasonably good health (able to do daily activities without major assistance).
- Your blood counts and kidney/liver function are at safe levels as determined by blood tests.
- You have no other serious health conditions like active infections, heart problems, or other cancers that are not well-controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding nimotuzumab (a targeted antibody) to Lonsurf (a chemotherapy pill) can help people with metastatic colorectal cancer that has not responded to at least two prior treatments. It is for patients whose tumors have specific genetic markers (RAS and BRAF wild-type, MSS/pMMR) and who have previously benefited from an EGFR-blocking drug like Erbitux or Vectibix.
This trial tests a new drug called LPM6690176 combined with chemotherapy and Avastin (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. It may be an option for those who haven't had treatment for their advanced cancer or have already tried one line of therapy.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.